Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.20344/amp.20532 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of Thrombopoietin Receptor Agonists on Pathophysiology of Pediatric Immune Thrombocytopenia.
Curr Issues Mol Biol
January 2025
Children & Adolescent Hematology-Oncology Unit, Second Department of Pediatrics, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Immune thrombocytopenia (ITP) in pediatric patients is a common cause of isolated thrombocytopenia. Various pathophysiological mechanisms are implicated in ITP pathogenesis, including the production of autoantibodies against components of platelets (PLTs) by B-cells, the activation of the complement system, phagocytosis by macrophages mediated by Fcγ receptors, the dysregulation of T cells, and reduced bone marrow megakaryopoiesis. ITP is commonly manifested with skin and mucosal bleeding, and it is a diagnosis of exclusion.
View Article and Find Full Text PDF[Immune thrombocytopenia in people under the age of twenty : a ten-year experience of a pediatric hematology and oncology department in Casablanca].
Rev Med Liege
January 2025
Service d'Hématologie clinique, CHU 20 Août, Casablanca, Maroc.
We conducted a retrospective study of 83 cases of immune thrombocytopenia (IT) in patients under 20 years of age. The aim was to provide an overview of IT in our young patients. The median age was 10 years, with a predominance of females (71 %).
View Article and Find Full Text PDFEltrombopag-Associated Cerebral Venous Sinus Thrombosis in Children.
Am J Ther
January 2025
The First Affiliated Hospital of Hunan Normal University Hunan Provincial People's Hospital, Hunan Province, Changsha City, Furong District (Tianxin Ge Yard), China.
Thrombopoietin Receptor Agonists for Thrombocytopenia in Pediatric Hematologic Malignancies.
Pediatr Blood Cancer
March 2025
Department of Pediatrics, Benioff Children's Hospitals, University of California, San Francisco, California, USA.
Background: Thrombopoietin receptor agonists (TPO-RAs) have demonstrated efficacy in treating clinically significant thrombocytopenia, including chemotherapy-induced thrombocytopenia in adults. However, data regarding their safety and efficacy in pediatric, adolescents, and young adult (AYA) patients with hematologic malignancies are limited.
Methods: We retrospectively identified 15 pediatric and AYA patients aged 25 years or younger with hematologic malignancies treated with a TPO-RA at UCSF Benioff Children's Hospitals between 2015 and 2023.
Clinical Improvement Without Increased Platelet Count With Eltrombopag in X-Linked Thrombocytopenia.
Pediatr Blood Cancer
March 2025
Division of Pediatric Hematology and Oncology, Department of Pediatrics, Maimonides Children's Hospital, Brooklyn, New York, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!